#China #Shanghai #biopharmaceuticals #Drug Development #Sanyou Bio

Sanyou Bio Honored with 2025 Best Customer Satisfaction CRO Award

On August 1st, 2025, the China Bio Innovation Expo held its grand annual ceremony in Suzhou, where Sanyou Bio received the highly coveted 2025 Best Customer Satisfaction CRO Award. This prestigious recognition highlights the company's exceptional performance and deep expertise in preclinical research and new drug development in the biopharmaceutical industry. Sanyou's commitment to excellence and its focus on innovation have resonated within the sector, earning respect from peers and industry leaders alike.

The award serves not only as an acknowledgment of Sanyou Bio's impressive accomplishments in the past but also as a driving force for future growth. Company representatives expressed gratitude towards their partners and colleagues for their unwavering support, emphasizing a shared commitment to innovation in biopharmaceutical research and development (R&D). With a strong foundation built on customer satisfaction and a track record of success, Sanyou Bio aims to continue advancing the frontiers of drug discovery and clinical research.

About Sanyou Biopharmaceuticals

Established in Shanghai, Sanyou Biopharmaceuticals stands out in the competitive landscape as a forward-thinking company dedicated to antibody drug discovery and development. With a super-trillion antibody library, alongside both AI and wet-lab R&D capabilities, Sanyou is on a mission to simplify the process of innovative biologics R&D for clients around the globe. By merging cutting-edge technology with an intelligent R&D framework, Sanyou has created an integrated platform that skillfully balances computational and laboratory techniques.

Sanyou's comprehensive approach accelerates global efforts in drug discovery through four key dimensions: new drug discovery, preclinical research, AI-driven drug development, and frontier scientific research. This multi-faceted strategy positions Sanyou at the forefront of the biopharmaceutical industry, fostering relationships with over 1,200 pharmaceutical and biotech organizations worldwide.

Having completed an impressive 1,200 projects associated with new drug discovery and development, including more than 50 collaborative R&D projects, Sanyou has established itself as an industry leader. Notably, nine of its projects have successfully navigated the investigational new drug (IND) submission process, highlighting its capacity for bringing innovations from concept to reality.

Sanyou maintains a robust global presence, with subsidiaries located in the United States and Europe, complemented by over 20,000 square meters of operational or developing R&D and GMP-compliant facilities. The company’s 4C service solution set encompasses CRO, CDO, CPO (Collaborative Project Organization), and CRS (Core Reagent Solutions) services, providing a comprehensive support system for clients.

Recognized as a National High-tech Enterprise and a Specialized and Innovative Enterprise within Shanghai, Sanyou is also celebrated as a “Little Giant” Enterprise and a “Zhangjiang Star” Enterprise, reflecting its status as a trailblazer in the biotechnology landscape. With a commitment to future advancements and customer satisfaction, Sanyou Bio is poised to continue leading the way in biopharmaceutical innovation.

Conclusion

As Sanyou enters an exciting new chapter following the award, the company looks forward to harnessing innovation and collaboration to achieve its ambitious goals in biopharmaceutical R&D. The recognition from the China Bio Innovation Expo underscores Sanyou Bio’s impact in the industry, and the team is eager to pursue new milestones in drug development, continuing to enhance the therapeutic landscape.